MetaCap

Eikon Therapeutics (EIKN) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eikon Therapeutics is the larger company by market cap ($256.8 million vs $245.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EIKN-68.40%LXEO-57.04%
+12%-30%-72%
Feb 5, 20261 yearNov 20, 2026
EIKN-67.31%LXEO-58.66%
+7%-32%-71%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EIKN versus LXEO key metrics
MetricEIKNLXEO
Share price$4.74$2.96
Market cap$256.84M$245.05M
1-day change-0.42%+0.34%
YTD return—-70.19%
1-year return—-67.33%
EPS (TTM)$-7.86$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-100.00M
52-week high$17.40$10.99
52-week low$4.72$2.55
Distance from 52-week high-72.76%-73.07%
Analyst consensusbuystrong_buy
Avg. price target upside+406.33%+748.31%
Average volume560.40K1.98M
Shares outstanding54.19M82.79M
Employees38468
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eikon Therapeutics

EIKN stock →

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

EIKN vs LXEO FAQ

Which is bigger, Eikon Therapeutics or Lexeo Therapeutics?

Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $245.05M for Lexeo Therapeutics (LXEO).

Are Eikon Therapeutics and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons